X4 PHARMACEUTICALS, INC — Net Income by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/a229616f-277c-4b84-951c-0d1fcc3e1e8b/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-79.2M | 2025-01-01 – 2025-12-31 | evidence 0001501697-26-000018 |
| FY 2024 | $-37.5M | 2024-01-01 – 2024-12-31 | evidence 0001628280-25-014805 |
| FY 2023 | $-101.2M | 2023-01-01 – 2023-12-31 | evidence 0001628280-24-012578 |
| FY 2022 | $-93.9M | 2022-01-01 – 2022-12-31 | evidence 0001628280-23-008745 |
| FY 2021 | $-88.7M | 2021-01-01 – 2021-12-31 | evidence 0001628280-22-006547 |
| FY 2020 | $-62.1M | 2020-01-01 – 2020-12-31 | evidence 0001628280-21-005202 |
| FY 2019 | $-52.8M | 2019-01-01 – 2019-12-31 | evidence 0001628280-20-003484 |
| FY 2018 | $-33.3M | 2018-01-01 – 2018-12-31 | evidence 0001628280-20-003484 |
| FY 2017 | $-22.0M | 2017-01-01 – 2017-12-31 | evidence 0001628280-20-003484 |
| FY 2016 | $-23.0M | 2016-01-01 – 2016-12-31 | evidence 0001564590-19-007097 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
X4 PHARMACEUTICALS, INC — all facts · Revenue · Operating Income